The global Drug and Gene Delivery Devices Market is estimated to be valued at US$152.2 Thousand in 2022 and is expected to exhibit a CAGR of 11.6% over the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Drug and gene delivery devices are designed to deliver therapeutic substances to targeted cells or tissues in the body, allowing for efficient and precise treatment of various diseases. These devices play a crucial role in the field of biotechnology and healthcare, as they enable the delivery of advanced therapies such as gene therapy, cell therapy, and immunotherapy. The increasing prevalence of chronic diseases and the growing demand for personalized medicine have driven the need for effective drug and gene delivery devices. These devices offer advantages such as precise targeting, reduced side effects, and improved patient outcomes, thereby making them essential in modern medical practice.
Market Key Trends:
An emerging trend in the drug and gene delivery devices market is the development of novel delivery systems for advanced therapies. With the increasing popularity of gene therapy and cell-based therapies, there is a growing demand for innovative delivery devices that can efficiently deliver therapeutic substances to the desired target. Companies in the market are investing in research and development to create advanced delivery systems that can overcome the challenges associated with these therapies, such as limited cell penetration and immune system response. This trend is expected to drive market growth, as healthcare providers and pharmaceutical companies recognize the importance of effective delivery systems for the success of advanced therapies.
The drug and gene delivery devices market can be segmented based on product type, application, and end-user. In terms of product type, the dominant segment is expected to be injectable devices. Injectable devices are widely used for delivering drugs and gene therapies directly into the bloodstream, providing precise and targeted delivery. They are efficient in delivering therapeutic agents to specific tissues and organs, and offer advantages such as ease of use and patient compliance. The increasing advancements in needle-free injection technologies and the growing demand for self-administration of drugs are expected to drive the growth of the injectable devices segment in the drug and gene delivery devices market.
The global Drug And Gene Delivery Devices Market Size is projected to witness high growth, exhibiting a CAGR of 11.6% over the forecast period. This growth can be attributed to various factors, including the increasing prevalence of chronic diseases, the rising demand for targeted therapies, and advancements in drug delivery technologies. The market is expected to reach a value of US$ 152.2 Thousand in 2022.
In terms of regional analysis, North America is expected to dominate the drug and gene delivery devices market. Factors such as the presence of a well-established healthcare infrastructure, increasing research and development activities, and high adoption rate of advanced drug delivery technologies contribute to the region’s dominance. Additionally, the region has a large number of key market players, which further fuels the market growth in North America.
Key players operating in the drug and gene delivery devices market include Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton Dickinson and Company, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others. These key players are engaged in strategic collaborations, mergers and acquisitions, and investments in research and development to strengthen their market position and gain a competitive edge.